Peptide Side Effects: What to Expect by Class, Route, and Trial Evidence

Peptide side effects fall into three broad categories: injection-site reactions, gastrointestinal effects concentrated in GLP-1 receptor agonists, and class-specific physiological effects. Severity and frequency depend more on compound class and route of administration than on brand name — and for research-grade peptides, product purity itself shapes the risk profile. This guide breaks down the evidence by class, by route, and by what's actually been measured in trials.

For the broader landscape, Peptigrity's lab test database currently holds 4,396 independent HPLC purity tests across 65 tracked peptides and 196 shops (verified May 2026) — a useful adjunct to side-effect reading because adulteration is itself a side-effect vector. The single most-tested compound on the platform is retatrutide with 445 tests, followed by BPC-157 at 303 and semaglutide at 184 — a ranking that mirrors where buyer-side safety concern is concentrating.

What are the most common peptide side effects?

The most common peptide side effects cluster into three categories: injection-site reactions (redness, lumps, soreness — near-universal across all injectable peptides), gastrointestinal effects (nausea, vomiting, diarrhea, constipation, delayed gastric emptying — concentrated in GLP-1 and GIP/GLP-1 agonists like semaglutide, tirzepatide, and retatrutide), and class-specific physiological effects (water retention with growth hormone secretagogues, transient flushing with melanocortin agonists, hunger spikes with ghrelin mimetics like GHRP-2 and GHRP-6). Severity is dose-dependent and route-dependent.

Three patterns matter when reading any side-effect claim. First, compound class predicts the dominant side-effect pattern far better than the peptide name — a GLP-1 receptor agonist will share the GI burden of every other GLP-1 receptor agonist, and a growth hormone secretagogue will share water retention with every other GH peptide. Second, long-term human safety data is robust only for FDA-approved peptides — semaglutide, tirzepatide, tesamorelin, and bremelanotide — and is minimal-to-absent for most research-grade peptides including BPC-157, MOTS-c, epitalon, and most bioregulators. Third, a meaningful share of what gets reported as "peptide side effects" in research-grade buying communities is caused by product-quality issues — endotoxin contamination, related impurities, or mis-identified compounds — not by the peptide itself. The buyer-controllable risk vector is real and is covered in detail later in this guide.

How does compound class predict side-effect pattern?

Mechanism predicts side-effect pattern. A peptide that activates GLP-1 receptors will share the GI-burden profile of every other GLP-1 receptor activator, regardless of brand name. A growth hormone secretagogue will share water retention with every other secretagogue. Knowing the mechanism class — not the marketing name — is the first step in anticipating what to expect. The table below maps the major peptide classes to their dominant side-effect patterns and to the strength of the underlying clinical evidence.

Each row links to the corresponding category pillar on Peptigrity for compound-level detail: GLP-1 and weight-loss peptides, growth hormone peptides, tissue-repair peptides, melanocortin and sexual wellness peptides, copper peptides and skin compounds, Khavinson bioregulators, immune and longevity peptides, and cognitive and neuroprotective peptides.

A skeptical framing worth holding in mind: cardiologist and academic Dr. Eric Topol's Peptide Craze essay argues that the evidence base for most non-GLP-1 peptides "is wanting" — much of what's claimed comes from preclinical models, not from human trials. The table above honors that distinction explicitly in the evidence column, and the rest of this guide does the same for every claim.

What are the side effects of GLP-1, dual-agonist, and triple-agonist peptides?

GLP-1 receptor agonists carry the most comprehensively documented side-effect profile of any peptide class — because they are the only class with thousands of patients followed for years in published Phase 3 trials. Semaglutide, tirzepatide, and retatrutide share a gastrointestinal-dominant profile (nausea, vomiting, constipation or diarrhea, delayed gastric emptying) that escalates with dose and with the breadth of receptor agonism. Triple agonism adds glucagon-receptor activity on top of GIP and GLP-1, which intensifies the GI burden at equivalent dose levels.

The frequencies below come directly from registration-trial publications. Reading them in one place is the single most useful exercise for anyone evaluating this class.

Semaglutide (Ozempic / Wegovy / Rybelsus)

Semaglutide, a GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Ozempic, 2017) and chronic weight management (Wegovy, 2021), produced gastrointestinal adverse events in 74.2% of the semaglutide group versus 47.9% of placebo in the STEP 1 trial (Wilding et al., NEJM 2021, n=1,961). The most-cited individual rates: nausea 44.2%, diarrhea 31.5%, vomiting 24.5%, constipation 24.2%. Most events were mild-to-moderate, peaked during the dose-escalation period, and subsided over time. Discontinuation due to GI events was 4.5% on semaglutide versus 0.8% on placebo. The US label also carries a boxed warning for thyroid C-cell tumors based on rodent data, plus warnings for pancreatitis, gallbladder events, acute kidney injury secondary to dehydration, and diabetic retinopathy complications in type 2 diabetes. The SELECT trial (NEJM 2023) added multi-year cardiovascular outcomes data — semaglutide reduced major adverse cardiovascular events by 20% in adults with obesity and established cardiovascular disease, with a safety profile consistent with STEP. Detailed semaglutide dosing and titration is covered in our semaglutide dosing chart and units conversion guide.

Tirzepatide (Mounjaro / Zepbound)

Tirzepatide, a dual GIP/GLP-1 receptor agonist approved by the FDA in 2022 (Mounjaro for T2D) and 2023 (Zepbound for obesity), shows GI rates that climb with dose in SURMOUNT-1 (Jastreboff et al., NEJM 2022, n=2,539): nausea 24.6%/33.3%/31.0% at 5/10/15 mg, diarrhea 18.7%/21.2%/23.0%, constipation 16.8%/17.1%/11.7%, vomiting 8.3%/10.7%/12.2%. A pooled 2025 analysis of SURMOUNT-1 to -4 in Diabetes, Obesity and Metabolism (Rubino et al.) found that 27.8% to 72.8% of tirzepatide participants reported at least one GI adverse event, versus 12.2% to 32.5% on placebo. Most were mild-to-moderate and transient.

Two tirzepatide-specific concerns deserve a flag. The first is hair loss — SURMOUNT-1 reported alopecia in roughly 5.7% of participants on 15 mg versus 1.0% on placebo, a secondary-endpoint finding that has driven significant community discussion. Our tirzepatide side effects deep-dive covers the hair-loss data and management strategies in depth. The second is lean mass loss — a class-wide concern flagged by Dr. Peter Attia in his analysis of the downside of GLP-1 receptor agonists. Roughly 25% to 40% of the weight lost on GLP-1 agonists is fat-free mass — a concern that drives current research interest in co-administering amylin analogs like cagrilintide to preserve muscle.

Retatrutide (investigational triple agonist)

Retatrutide, an investigational once-weekly triple agonist (GLP-1, GIP, and glucagon receptors) developed by Eli Lilly, is currently in Phase 3 trials including TRIUMPH. In the Phase 2 trial (Jastreboff et al., NEJM 2023, n=338), adverse events were reported in 73% to 94% of retatrutide groups versus 70% of placebo, with gastrointestinal events dominating: nausea, vomiting, diarrhea, dyspepsia, and constipation, all dose-related and mostly mild-to-moderate. Nausea approached 60% at the 12 mg dose. Discontinuation due to AEs occurred in 6% to 16% of retatrutide participants versus 0% of placebo. Adverse events of interest included one case of acute pancreatitis and reports of serious gastrointestinal symptoms and cardiac arrhythmias. The Phase 3 TRIUMPH-4 trial subsequently identified dysesthesia as an emerging signal at the 9 mg and 12 mg doses — a new safety finding not prominent in the Phase 2 data.

Retatrutide's full side-effect landscape — including the TRIUMPH dysesthesia signal, the dose-escalation schedule's effect on GI burden, real-world community reports, and what to monitor by week — is covered in our dedicated retatrutide side effects guide. It is the single most-asked-about compound on Peptigrity, with retatrutide accumulating 445 independent HPLC tests on the platform (verified May 2026) — more than any other peptide tracked.

Compounded versus FDA-approved GLP-1s

A 2024 cross-sectional study in Obesity (PMC11703442) examined the direct-to-consumer market for compounded GLP-1 receptor agonists in Colorado and found numerous misleading claims about regulatory status, off-label indications, and side-effect risk. One compounded product even advertised BPC-157 as an additive — a substance the FDA had explicitly determined to be unsafe for compounding at that time. The implication for buyers: published trial AE rates apply to the FDA-approved formulation; compounded or research-grade GLP-1s carry an additional uncertainty layer because the product itself may not be what the label says. See our compounding pharmacy versus research peptide comparison and comparing semaglutide and tirzepatide for the full framing.

What are the side effects of growth hormone peptides?

Growth hormone peptides act on two distinct pharmacological pathways. GHRH analogs (sermorelin, tesamorelin, CJC-1295 with DAC) stimulate the pituitary's growth hormone-releasing hormone receptor. GHRPs (ipamorelin, GHRP-2, GHRP-6, hexarelin) mimic ghrelin. The side-effect profiles separate along this line: GHRH analogs are generally cleaner, while less-selective GHRPs add appetite stimulation and minor cortisol/prolactin elevation on top of the shared water-retention and injection-site effects.

GHRH analogs

Tesamorelin (Egrifta), the only FDA-approved peptide in this subclass (approved for HIV-associated lipodystrophy in 2010), has the most complete safety record. Common adverse events in registration trials included injection-site reactions, arthralgia, peripheral edema, and myalgia, with rare reports of glucose intolerance worsening. The DailyMed Egrifta label remains the authoritative reference for the AE profile.

Sermorelin (Geref) was FDA-approved in 1997 for pediatric GH deficiency and withdrawn from the US market in 2008 for commercial reasons — not for safety. It remains compoundable in the US under physician prescription. Reported effects are predominantly mild and centered on injection-site reactions, flushing, and transient headache.

CJC-1295 (with or without DAC) lacks FDA approval and is studied predominantly in small Phase 1 and 2 trials. Reported AEs in human studies are mild — injection-site reactions, transient flushing — with longer-half-life formulations (with-DAC) potentially producing more sustained GH/IGF-1 elevation and the secondary effects that come with it (numbness or tingling, mild carpal-tunnel-like symptoms, fluid retention). The distinction between with-DAC and without-DAC matters here; our CJC-1295 with versus without DAC comparison covers the pharmacokinetic and dosing implications.

GHRP class

Ipamorelin is the most selective ghrelin mimetic in common use — it stimulates GH release without significantly elevating cortisol or prolactin. The reported AE profile is mild: injection-site reactions, mild headache, transient flushing. GHRP-2 (pralmorelin) and GHRP-6 are older, less-selective compounds that produce stronger appetite stimulation (an intended effect for some users, a side effect for others) along with mild cortisol and prolactin elevation — a profile that has kept both expected to remain on the FDA's "do not compound" list. Hexarelin is the most potent in the class and has documented cardiac effects in animal studies; its use is generally restricted to research contexts.

A common combination — CJC-1295 with Ipamorelin — pairs the sustained GH-releasing pulse of a GHRH analog with the pulsatile burst of a selective ghrelin mimetic. The stacked AE profile is largely additive: injection-site reactions, mild flushing, transient hunger spikes, and dose-dependent water retention. Numbness or tingling in the hands and feet, often described as carpal-tunnel-like symptoms, can appear at higher doses or with prolonged use as elevated IGF-1 increases extracellular fluid.

What are the side effects of tissue repair, immune, cognitive, and skin peptides?

Tissue-repair, immune, cognitive, and skin peptides span a wide evidence range — from FDA-approved (PT-141, tesamorelin, Thymosin Alpha-1 internationally) to predominantly preclinical (BPC-157, MOTS-c, most bioregulators). Side-effect profiles are correspondingly uncertain: when the evidence base is small-n rodent studies plus community reports, the honest answer is that long-term safety in humans is not established. The table below maps each compound to its evidence tier and most-reported AEs.

BPC-157 — the most-asked compound on safety questions

BPC-157, a synthetic 15-amino-acid pentadecapeptide (MW 1,419.5 Da) derived from a fragment of a protective protein found in human gastric juice, has been studied in more than 100 preclinical models by Prof. Predrag Sikirić's group at the University of Zagreb. A 28-day repeated-dose toxicology study in rats (4, 1, or 0.2 mg/kg/day intramuscular) and beagle dogs (2, 0.5, or 0.1 mg/kg/day) showed no significant toxicity at multiples of the typical research dose — but this is animal data, not human data. The first registered Phase 1 human safety trial (oral, 2024) reported no serious adverse events, but the sample was small and outcomes were short-term.

The community concern most worth addressing directly is cancer risk via angiogenesis: BPC-157 promotes blood vessel formation, and angiogenesis is also a hallmark of tumor growth. The Sikirić group's 2025 commentary in Pharmaceuticals argued against this concern on mechanistic grounds — proposing that BPC-157's NO-system modulation maintains protective functions while limiting cytotoxic over-activation. No human clinical data exists either way, and the honest framing is that long-term oncological safety is unknown. For mechanism detail, see our BPC-157 science and healing mechanism deep-dive.

TB-500 (Thymosin β4 fragment)

TB-500 is a synthetic peptide fragment of Thymosin β4. The first Phase 1 human safety trial (PMID 34346165, 2021) reported no significant toxicity. Community-reported AEs are dominated by injection-site reactions. Like BPC-157, the long-term human safety profile is not established. For combined-protocol use, see our BPC-157 and TB-500 stack guide.

GHK-Cu

GHK-Cu, the tripeptide-copper complex first characterized by Dr. Loren Pickart in the 1970s, has the cleanest human safety data of any non-GLP-1 research peptide — but only via the topical route, where dermatology trials have established a benign profile. Systemic injection is less characterized; theoretical concerns include copper accumulation with chronic high-dose use without monitoring. Skin irritation, contact dermatitis, and transient green discoloration at higher topical concentrations are the most-reported topical AEs.

KPV

KPV is the C-terminal tripeptide of α-MSH and has been studied in preclinical inflammation models, particularly for inflammatory bowel disease. Search-trend data shows rising community concern, including a specific cluster around "KPV peptide side effects liver" — these queries reflect forum speculation that has minimal published support. No case reports of liver toxicity exist in the peer-reviewed literature, and no long-term human safety data exists either. The honest answer is that the evidence base is too sparse to characterize the AE profile.

PT-141 (bremelanotide) and Melanotan II

PT-141 — bremelanotide, FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women — has the most complete AE profile in the melanocortin class. The Vyleesi label documents nausea in approximately 40% of users, flushing in 20%, injection-site reactions, transient blood pressure elevation averaging about 6 mmHg systolic, and focal hyperpigmentation (darkening of gums, face, or breasts) with repeated dosing.

Melanotan II shares the melanocortin mechanism but with broader receptor activity (MC1R for pigmentation plus MC4R). Reported AEs include nausea, flushing, spontaneous erections, and most concerning, case reports of new or changing melanocytic lesions and one published case of dysplastic nevi development. MT-II is expected to remain on the FDA's Category 2 "do not compound" list precisely because of these signals.

MOTS-c, DSIP, SS-31, and the rest

MOTS-c — a 16-amino-acid mitochondrial-derived peptide discovered by Dr. Changhan David Lee's group at USC — has injection-site reactions as the dominant community-reported AE. Systemic effects are minimally characterized in published human data. DSIP, SS-31, Selank, Semax, Epitalon, and Thymosin Alpha-1 each fall somewhere between preclinical-dominant and approved-outside-the-US, and their AE profiles reflect those evidence tiers.

The academic skepticism that academic peptide-therapy chemist Eileen Kennedy (UNC Eshelman School of Pharmacy) voiced in the March 2026 NPR coverage of the FDA reclassification — that human trial evidence for popular grey-market peptides remains weak — applies most directly to compounds in this section.

How do side effects differ by route of administration?

Route of administration shapes side-effect pattern as much as compound class does. Subcutaneous injection — the most common route for research peptides — produces a predictable injection-site profile that overlaps closely with the insulin-injection literature. Intramuscular shifts the profile toward deeper soreness. Intranasal substitutes nasal irritation for skin reactions. Oral routes introduce gastrointestinal first-pass effects. Topical adds skin-specific concerns. The table below summarizes the route-by-route differences.

The mechanics of getting these routes right matter for AE rates. Our how to inject peptides guide, the subcutaneous versus intramuscular injection comparison, and the intranasal peptide technique guide cover the technique details that move site reactions from frequent to rare.

Lump or normal reaction? A decision frame for injection-site lumps

The single most-asked question across the GLP-1 user communities is what to do about a lump at the injection site. The answer depends on which of four distinct phenomena is producing the lump.

Granulation or sterile firmness (most common) presents as a small, soft, slightly tender area appearing within hours of injection and resolving within 2–5 days. No action needed beyond site rotation. Lipohypertrophy presents as a firm, painless area of thickened subcutaneous tissue that develops with chronic same-site injection — common with daily-injected compounds. Rotation to a new site allows the area to gradually normalize over weeks. Sterile abscess or local immune reaction presents as a tender, red, sometimes warm lump that may persist longer than a week without clear resolution. This warrants medical evaluation — and is also the pattern most often produced by an impurity or endotoxin in the product, which is the topic of the next section. Infection presents with fever, expanding redness, warmth, and increasing rather than decreasing pain over 24–48 hours. This is a same-day medical consult.

If a lump persists firm and tender for more than 7–10 days, or if any sign of expanding redness, warmth, or systemic symptoms (fever, chills) appears, treat it as a clinical question rather than a peptide-protocol question.

Can impure, contaminated, or mis-identified peptides cause side effects you'd blame on the peptide?

A meaningful share of what gets reported as "peptide side effects" in research-grade buying communities is not caused by the peptide at all — it is caused by what else is in the vial. Endotoxin contamination, related impurities (deamidation products, truncated sequences, oxidized variants), mis-identified compounds, and sub-potent dosing all produce symptom patterns that mimic or amplify true pharmacological side effects. This is the single buyer-controllable side-effect risk vector, and it deserves its own treatment because every wellness-clinic side-effect article in this space ignores it.

Endotoxin contamination produces fever, chills, injection-site induration, and systemic flu-like reactions — a pattern that gets routinely misattributed to the peptide itself. The Limulus Amebocyte Lysate (LAL) assay is the standard test for endotoxin presence, and many third-party testing labs include it in CoA panels. Our peptide endotoxin testing and LAL assay interpretation guide covers the test methodology and what acceptable values look like.

Peptide impurities present an even broader risk surface. A 2008 Journal of Peptide Science analysis (PMC2238048) of commercial synthetic peptides documented what's actually inside some vials sold as research-grade — truncated sequences, racemized residues, deletion peptides, oxidation products of methionine and tryptophan residues. The 2% impurity floor in a 98%-pure peptide is exactly where the unknown-AE risk lives. Our reference for the buyer-side threshold is the peptide purity standards guide — most research-grade peptides should meet ≥98% HPLC purity, with identity confirmed by mass spectrometry.

Mis-identified peptides are rarer but consequential. A vial labeled "BPC-157" containing a different compound entirely will produce an AE pattern matching the actual contents, not the label. Mass spectrometry identity confirmation — looking for the correct molecular ion — matters here. Our mass spectrometry for peptide identity verification guide and the guide to reading HPLC and MS lab test results cover the reading skills involved.

Sub-potent dosing — paradoxically — is also a "side effect": no effect at all is attributed to peptide intolerance or non-response when the actual problem is that the product is significantly under-dosed. A 5 mg vial that delivers 2 mg of active peptide is a quality failure, and quality failures are detectable by independent HPLC.

This is exactly what Peptigrity's data moat is for. The platform's lab-test database holds 4,396 independent HPLC purity tests across 65 tracked peptides and 196 shops (verified May 2026), updated continuously as new tests land. Recent receipts include a BPC-157 sample tested at 99.0% purity at Modern Aminos and a retatrutide sample at 99.9% purity at Pura Peptide. The point isn't that any single shop is "the answer" — Peptigrity is editorially independent and recommends none — but that having a cross-vendor independent dataset lets buyers reduce contamination-as-side-effect risk before purchase rather than rationalizing it afterward.

Two further references close this section out. The red flags in peptide certificates of analysis guide covers what to look for on a CoA — and what manipulation patterns to watch for. The GMP versus non-GMP peptide manufacturing comparison covers the upstream manufacturing-quality picture.

When are side effects a reason to stop using a peptide?

Most peptide side effects fall into one of three response categories: stop immediately and seek medical attention, stop and reconsider the protocol, or manage without stopping. Knowing which category a symptom falls into matters more than a fixed rule, and the right call is usually a conversation with a healthcare provider — particularly for FDA-approved peptides where a prescribing clinician is already in the loop. The table below summarizes the decision pattern.

The most useful question to ask when an unexpected AE appears is whether the symptom pattern matches the class. A GLP-1 user with nausea during titration is on a predictable track. A BPC-157 user with sudden fever and rigors hours after injection is not — that pattern fits endotoxin contamination far better than it fits BPC-157, and the next step is a CoA review and ideally an independent lab test of the vial in hand.

For the regulatory backdrop — particularly relevant if discontinuation is forced by an external change rather than a medical one — the FDA's April 15, 2026 removal of 12 peptides (including BPC-157, TB-500, MOTS-c, GHK-Cu injectable, Melanotan II, Semax, and PEG-MGF) from the Category 2 "do not compound" list does not yet confer Category 1 status; the Pharmacy Compounding Advisory Committee meeting scheduled for July 23–24, 2026 will review specific peptides for inclusion on the 503A bulks list. As of May 2026, formal reclassification remains pending. Our legal status of peptides by country guide and the FDA peptide regulation 2025–2026 timeline cover the broader landscape.

Frequently Asked Questions

Do peptides have long-term side effects?

Long-term side-effect data is robust for FDA-approved peptides and minimal for most research-grade peptides. The SELECT cardiovascular outcomes trial for semaglutide (NEJM 2023) provides multi-year safety data including reduced major adverse cardiovascular events; SURMOUNT-1 published 176-week follow-up data for tirzepatide. For BPC-157, MOTS-c, KPV, Epitalon, and most other non-approved peptides, no long-term human safety data exists — preclinical animal studies span weeks to months, not years. The honest framing for research peptides is that long-term effects are unknown.

Are peptide injection-site lumps normal?

Small, soft, mildly tender lumps that resolve within 2–5 days are mechanical and normal. Firm painless areas at chronically used sites suggest lipohypertrophy and respond to site rotation. Tender, red, warm lumps persisting longer than a week deserve medical evaluation and may also indicate product-quality issues — endotoxin contamination produces this exact pattern. Fever, expanding redness, or increasing pain over 24–48 hours indicates possible infection and is a same-day clinical question.

Can BPC-157 cause cancer?

No human data exists either way. BPC-157 promotes angiogenesis (new blood vessel formation), and angiogenesis is also a feature of tumor growth — which is why the question keeps coming up. The Sikirić group's 2025 commentary in Pharmaceuticals argues against the concern on mechanistic grounds, proposing that BPC-157 modulates the NO system to preserve protective rather than cytotoxic effects. This is a mechanistic argument, not a clinical one. Long-term oncological safety in humans has not been studied. Anyone using BPC-157 with a personal or family history of cancer should treat that fact as a reason to consult an oncologist.

Why am I more nauseous on retatrutide than on semaglutide?

Receptor breadth. Retatrutide adds glucagon-receptor activity on top of GIP and GLP-1, which intensifies the GI burden at equivalent dose levels. In the Phase 2 trial, nausea climbed to approximately 60% at the 12 mg dose, and 6–16% of retatrutide participants discontinued for AEs versus none on placebo. The full per-dose AE breakdown and titration management strategies are in the retatrutide side effects guide.

Do peptides interact with my other medications?

GLP-1 receptor agonists slow gastric emptying and can affect the absorption of orally administered medications — particularly drugs with narrow therapeutic windows or time-sensitive absorption profiles. This is the most-documented interaction class. Beyond the GLP-1 family, most peptide-medication interactions are unstudied. Disclose any peptide use to a prescribing clinician, particularly before any new prescription.

Can I get peptide side effects from oral or topical peptides?

Yes. Oral semaglutide (Rybelsus) produces the GLP-1-class GI profile with somewhat higher dyspepsia and abdominal pain rates than the subcutaneous formulation. Topical copper peptides can cause skin irritation, contact dermatitis, or copper-related discoloration at high concentrations. Collagen peptide supplements have a different — and milder — GI and allergenic profile that's outside the scope of this guide.

How long do peptide side effects last?

Most acute effects — injection-site redness, mild nausea — resolve within hours to a few days. Titration-related GI effects on GLP-1 agonists typically fade as the body adapts, generally over 1–4 weeks after each dose step. Chronic effects (water retention with GH peptides, hyperpigmentation with melanocortin agonists) persist as long as dosing continues. For the broader timing landscape of peptide action, see how long peptides take to work.

This article is for educational and informational purposes only and does not constitute medical advice. Peptides discussed may be investigational compounds not approved by the FDA (or equivalent regulators in your jurisdiction) for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.